FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Anand Shah(Rutgers, The State University of New Jersey), Richard Pazdur(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Gideon M. Blumenthal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wentao Fu(Center for Drug Evaluation and Research), Shenghui Tang(United States Food and Drug Administration), William F. Pierce(United States Food and Drug Administration), Todd R. Palmby(University of North Carolina at Chapel Hill), Paresma Patel(Center for Drug Evaluation and Research), Elleni Alebachew(United States Food and Drug Administration), Kirsten B. Goldberg(United States Food and Drug Administration), Youwei Bi(Center for Drug Evaluation and Research), Qi Liu(Hebei Medical University), Jingyu Yu(Center for Drug Evaluation and Research), Ping Zhao(Third People's Hospital of Chengdu), C.J. George Chang(Center for Drug Evaluation and Research), Amy Tilley(Center for Drug Evaluation and Research), Julia A. Beaver(Center for Drug Evaluation and Research), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Erik Bloomquist(Center for Drug Evaluation and Research)
Cited by 115
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k